Celix Pharmaceuticals
  • Anmelden

  • Mein Konto
  • Angemeldet als:

  • filler@godaddy.com


  • Mein Konto
  • Abmelden

  • About us
  • Team
  • Products
  • Business Development
  • Sustainability
  • News
  • Careers
  • Contact us
  • Mehr
    • About us
    • Team
    • Products
    • Business Development
    • Sustainability
    • News
    • Careers
    • Contact us
Celix Pharmaceuticals

Angemeldet als:

filler@godaddy.com

  • About us
  • Team
  • Products
  • Business Development
  • Sustainability
  • News
  • Careers
  • Contact us

Konto


  • Mein Konto
  • Abmelden


  • Anmelden
  • Mein Konto

Celix Pharma announces the launch of Dimethyl Fumarate GR Capsules

5th February 2024   

Celix Pharma is pleased to announce the launch of Dimethyl Fumarate Gastro-resistant hard capsules, on day 1 post expiry of the marketing exclusivity for Tecfidera® in the UK. Dimethyl fumarate 120mg, 240mg GR capsules are supplied in blister packs containing 14 or 56 capsules. 

Details

Celix Pharma announces the launch of Vecicom® (Tapentadol) Prolonged-release (PR) tablets

2nd February 2024   

Celix Pharma is pleased to announce the launch of Vecicom® (Tapentadol) Celix Prolonged-release (PR) tablets. Vecicom® (Tapentadol) 50mg, 100mg, 150mg, 200mg and 250mg PR tablets are supplied in blister packs containing 28 or 56 tablets. 

Details

Celix Pharma reports profitability in its first year of commercial operations

London, 27th November 2023  

Celix Pharma, a start-up generic pharmaceutical company based in London, is pleased to announce its achievement of profitability in its inaugural year of commercial operation: FY 22-23

Details

Celix Pharma announces the launch of Vecit® MR Tablets (Solifenacin / Tamsulosin)

8th May 2023

Celix Pharma is pleased to announce the launch of Vecit® 6mg / 0.4 mg Modified-release Tablets (Solifenacin / Tamsulosin) on loss of market exclusivity for Vesomni® in the UK. Vecit® MR tablets are supplied in blister (patient) packs containing 30 tablets. 

Details

Celix Pharma announces the launch of Sitagliptin + Metformin tablets.

7th Apr 2023  

Celix Pharma is pleased to announce the launch of Sitagliptin/Metformin 50mg/1000mg film-coated tablets on loss of exclusivity in the UK. Sitagliptin/Metformin are supplied in blister (patient) packs containing 56 tablets.  

Details

Celix Pharma announces the launch of Bexarotene soft-gel Capsules

3rd Jan 2023  

Celix Pharma is pleased to announce the launch of Bexarotene 75mg soft-gel capsules in the UK. Bexarotene 75mg is available in a child-resistant, HDPE bottle pack containing 100 capsules. 

Details

Celix Pharma announces the launch of Sitagliptin Tablets

27th Sep 2022

Celix Pharma is pleased to announce the launch of Sitagliptin 25mg, 50mg and 100mg film-coated tablets on loss of exclusivity in the UK. All 3 strengths are available in blister packs of 28 tablets. 

Details

Celix Pharma announces the launch of Abiraterone Tablets

08th Sep 2022

Celix Pharma is pleased to announce the launch of Abiraterone 500 mg film-coated tablets in the UK. Abiraterone 500mg is available in unit-dose blister packs of 56 tablets. 

Details

Celix Pharma announces the launch of Icatibant Inj. (in a PFS)

29th July 2022

Celix Pharma is delighted to announce the launch of Icatibant 30mg Solution for Injection in a pre-filled syringe. Icatibant is available in a pack of 1 syringe, with a separate needle. 

Details

Celix Pharma announces the launch of Pirfenidone Tablets

1st July 2022

Celix Pharma is excited to announce the launch of Pirfenidone 267mg, 801mg Film-coated Tablets in the UK.  The 267mg is available in blister packs of 63 and 252 tablets, whereas the 801mg is available in a blister pack of 84 tablets.  

Details

Celix Pharma announces the launch of its first product in the UK - Fesoterodine PR Tablets

18th May 2022 

Celix Pharma is excited to announce the launch of Fesoterodine fumarate 4mg, 8mg prolonged-release Tablets in the UK. Both strengths are available in blister (patient) packs of 28 tablets.

Details

Celix Pharma announces approval of Icatibant Solution for Injection in a pre-filled syringe.

27th April 2022
Celix Pharma is pleased to announce the grant of its Marketing Authorisation (MA) for Icatibant 30mg Solution for Injection in a pre-filled syringe by the MHRA. 

Details

Celix Pharma announces approval of Fesoterodine Prolonged-release Tablets

14th February 2022
Celix Pharma is pleased to announce its partners’ approval of a Marketing Authorisation (MA) for Fesoterodine fumarate 4mg and 8mg prolonged-release tablets by the MHRA.

Details

Celix Pharma announces approval of Abiraterone Film-coated tablets

14th December 2021
Celix Pharma is pleased to announce the grant of its Marketing Authorisation (MA) for Abiraterone 500mg Film-coated tablets by the MHRA.   

Details

Celix Pharma announces approval of its first product, Pirfenidone Tablets.

5th November 2021
Celix Pharma is pleased to announce the grant of its first Marketing Authorisation (MA) for Pirfenidone 267mg, 534mg and 801mg Tablets by the MHRA.  

Details

Celix Pharma raises GBP 2.5mn in seed funding round.

London,  21st  December 2020
Celix Pharma, a UK-based startup in the UK / EU generic pharmaceutical space, announced that it has raised GBP 2.5million in seed funding.  

Details

Copyright © 2020 Celix Pharma Ltd.

Company No. 12474195 (Registered in England & Wales)

All Rights Reserved.

  • Privacy Policy

Unterstützt von

Cookie Policy

This website uses cookies. By continuing to use this site, you accept our use of cookies. Privacy Policy

Accept & Close